A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data

被引：0
|
作者：
Schneeweiss, Andreas
Ruiz, Amparo
Manikhas, Alexey
Bottini, Alberto
Rovira, Pedro Sanchez
Mansouri, Kambiz
Kazeem, Gbenga
Bauknecht, Thomas
机构：
[1] Univ Heidelberg Hosp, Heidelberg, Germany
[2] Inst Valenciano Oncol, Valencia, Spain
[3] City Clin Oncol Dispensary, St Petersburg, Russia
[4] AO Ist Ospitalieri, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[5] Complejo Hosp Jaen, Jaen, Spain
[6] Lilly Deutschland GmbH, Bad Homburg, Germany
[7] Lilly United Kingdom, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [2] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    [J]. CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [3] Results of clinical endpoints of a randomized phase It trial with doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer
    Schneeweiss, A.
    Ruiz, A.
    Rovira, P.
    Bottini, A.
    Manikhas, A.
    Wacker, J.
    Schumacher, T.
    Wolf, M.
    Segui, M.
    Sinn, P.
    Kennedy, L.
    Mansouri, K.
    Bauknecht, T.
    [J]. BREAST, 2009, 18 : S63 - S63
  • [4] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [5] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    [J]. JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [6] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Giermek, J.
    Martin, M.
    Jasiowka, M.
    Mackey, J. R.
    Chan, A.
    Liu, M-C
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T. A.
    Bensfia, S.
    Hitler, S.
    Xu, N.
    Bee-Munteanu, V.
    Drevot, P.
    Press, M. F.
    Crown, J.
    [J]. CANCER RESEARCH, 2016, 76
  • [7] Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)
    Di Leo, A
    Crown, J
    Nogaret, LM
    Duffy, K
    Bartholomeus, S
    Dolci, S
    Rowan, S
    O'Higgins, N
    Riva, A
    Piccart, MJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S41 - S41
  • [8] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [9] Sequential doxorubicin plus vinorelbine (AV) followed by docetaxel plus carboplatin (DC) as neoadjuvant chemotherapy for advanced breast cancer (BC)
    Santisteban, Marta
    De la Cruz, Susana
    Sola, Jesus Javier
    Aramendia, Jose Manuel
    Espinos, Jaime
    Garran, Cristina
    Martinez-Regueira, Fernando
    Zornoza, Gerardo
    Fernandez-Hidalgo, Oscar
    Nieto, Yago
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 86 - 86
  • [10] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
    Puertolas, T
    Grandez, R
    de Lobera, AR
    Lao, J
    Herrero, A
    Trufero, JM
    Pazo, R
    Orduña, VA
    Cortes, AA
    Torres, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 89S - 89S
12345